CHEMOTHERAPY
Online ISSN : 1884-5894
Print ISSN : 0009-3165
ISSN-L : 0009-3165
Search
Advanced search
OR
Browse
Search
Volume 39, Issue Supplement4
Displaying 101-108 of 108 articles from this issue
Show all abstracts
  • CLINICAL EVALUATION OF SPARFLOXACIN IN PATIENTS WITH URINARY TRACT INFECTION
    Akio Nishino, Shuji Tokunaga, Haruo Hisazumi
    1991 Volume 39 Issue Supplement4 Pages 849-852
    Published: August 28, 1991
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.39.Supplement4_849
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Sparfloxacin, a new antimicrobial agent, was administered to patients with urinary tract infection. The overall efficacy rates in 7 patients with acute uncomplicated cystitis and in 10 patients with chronic complicated urinary tract infection were 100% and 70%, respectively. Mild temporary side effects were observed in 3 patients.
    View full abstract
    Download PDF (549K)
  • SPARFLOXACIN IN UROLOGICAL INFECTION
    Makoto Yanagawa, Katsumi Tsukamoto, Atsushi Yamashita, Hiromi Tochigi, ...
    1991 Volume 39 Issue Supplement4 Pages 853-856
    Published: August 28, 1991
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.39.Supplement4_853
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Sparfloxacin is characterized by a broad antibacterial spectrum covering Gram-positive and egative bacteria. We used this compound in the treatment of 18 patients with urinary tract infection (UTI) to investigate the drug's efficacy, safety and usefulness. Sparfloxacin was administered to 11 patients with acute uncomplicated cystitis and 7 with complicated UTI. The drug's efficacy was evaluated according to the criteria of the Japanese UTI Committee. In six assessable cases of acute uncomplicated cystitis, sparfloxacin was evaluated as excellent in 5 cases and moderate in 1 case. In seven assessable cases of complicated UTI, sparfloxacin was evaluated as excellent in 4 cases, moderate in 1 case and poor in 2 cases.
    View full abstract
    Download PDF (536K)
  • SPARFLOXACIN IN COMPLICATED URINARY TRACT INFECTIONS
    Shuichi Hida, Osamu Yoshida
    1991 Volume 39 Issue Supplement4 Pages 857-860
    Published: August 28, 1991
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.39.Supplement4_857
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We evaluated the clinical efficacy and safety of sparfloxacin, a new quinolone, in 20 patients with complicated urinary tract infections. The efficacy rates, judged by the criteria of the Japanese UTI Committee and a doctor's evaluation, were both 50%. In 11 cases with an indwelling catheter, the rate was 27.3% by the doctor's evaluation. The bacteriological eradication rate was 80.0%.
    There were no side effects or abnormal laboratory findings due to treatment.
    View full abstract
    Download PDF (510K)
  • CLINICAL EXPERIENCE WITH SPARFLOXACIN (SPFX) IN COMPLICATED URINARY TRACT INFECTIONS
    Shutaro Mizutani, Yuji Takano, Hiroshi Kameoka, Susumu Miyoshi, Norio ...
    1991 Volume 39 Issue Supplement4 Pages 861-866
    Published: August 28, 1991
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.39.Supplement4_861
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Twenty patients with complicated urinary tract infection were given sparfloxacin (150mg) twice a day orally for 5 days. Clinical effect was excellent in 7 cases, moderate in 8 and poor in 4, The overall efficacy rate was 79%.
    As to side effects, emotional lability was observed in one case and as an abnormal laboratory finding, a slight increase in eosinophil was noted in another case.
    View full abstract
    Download PDF (770K)
  • CLINICAL STUDY ON SPARFLOXACIN IN SURGICAL INFECTIONS
    Hiroshi Yamamoto, Hidehiko Shimura
    1991 Volume 39 Issue Supplement4 Pages 867-870
    Published: August 28, 1991
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.39.Supplement4_867
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Sparfloxacin (SPFX), a synthetic new quinolone antimicrobial, was evaluated for clinical efficacy and safety in 12 patients with surgical infections by orally administering at 100mg to 150mg twice daily for 3 to 10 days.
    The clinical response was excellent in 1 case, good in 8 and fairly good in 3, the efficacy rate being 75.0%.
    Sleepiness, probably as the drug-related side effect, was observed in only one case.
    View full abstract
    Download PDF (535K)
  • CLINICAL EXAMINATION OF SPARFLOXACIN IN OBSTETRICS AND GYNECOLOGY
    Tetsuro Chimura, Nobuyuki Morisaki, Tohru Funayama, Hiroshi Kanasugi, ...
    1991 Volume 39 Issue Supplement4 Pages 871-876
    Published: August 28, 1991
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.39.Supplement4_871
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Sparfloxacin (SPFX) is a new antibacterial agent derived from pyridonecarboxylic acid, We investigated the clinical efficacy of SPFX for obstetrics and gynecological infections.
    SPFX was orally administered to 8 patients with intrauterine infection, to 6 with cervicitis and to 1 each with Bartholin's abscess and peritonitis, using a daily dose of 200 or 300mg. The duration was 7 to 30 days. The clinical response was excellent in 10 cases and good in 5, and the efficacy rate was 100%. The bacteriological response was eradicated in 11 cases, and replaced in 2, and the eradication rate was 100%. As a side effect, mild pain of the fingers was seen in one case with cervicitis.
    From these results, we consider SPFX will be useful for obstetric and gynecological infections.
    View full abstract
    Download PDF (651K)
  • SPARFLOXACIN IN OBSTETRICS AND GYNECOLOGY
    Kayoko Hirano, Yasuo Kishimoto, Takafumi Kudo, Kaoru Sekiba, Yoshio Is ...
    1991 Volume 39 Issue Supplement4 Pages 877-883
    Published: August 28, 1991
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.39.Supplement4_877
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We performed a clinical study on sparfloxacin, a new pyridone carboxylic derivative, and obtained the following results.
    Sparfloxacin was administered orally at daily dose of 200-300mg for 4-12 days to 29 patients with obstetric and gynecological infection (Adnexitis, infected ovarian tumor, intrauterine infections and external genital infections).
    The clinical results were evaluated as excellent in 1 case and good in 28. The efficacy rate was 100%.
    In a bacteriological study, 16 organisms were isolated from 13 cases. Thirteen organisms were eradicated, the eradication rate being 81.3%.
    Side effects were observed in 4 cases which were administered orally at a daily dose of 300mg. No side effects were observed in any cases which were administered orally at a daily dose of 200mg.
    Our conclusion is that sparfloxacin is a useful drug for the treatment of obstetric and gynecological infections.
    View full abstract
    Download PDF (686K)
  • CLINICAL EFFECT OF SPARFLOXACIN (SPFX) ON EXTERNAL EYE DISEASES
    Koki Matsumoto, Ryoichi Okamura, Ryuji Kamata
    1991 Volume 39 Issue Supplement4 Pages 884-886
    Published: August 28, 1991
    Released on J-STAGE: August 04, 2011
    DOIhttps://doi.org/10.11250/chemotherapy1953.39.Supplement4_884
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We evaluated the clinical effect of sparfloxacin (SPFX), on 10 cases of external eye disease including conjunctivitis (5 cases), dacryocystitis (2), blepharoconjunctivitie (2) and canaliculitis (1). The drug was administered orally in doses of 200-300mg divided into two or three times a day for 7-8 days. The clinical response was excellent in 2 patients, good in 5, and fair in 3 No side effects were found in any of the patients.
    View full abstract
    Download PDF (323K)
feedback
 Top